罗格列酮联合胰岛素治疗2型糖尿病的临床疗效观察

目的观察罗格列酮应用于单用胰岛素治疗血糖控制欠佳的2型糖尿病患者的疗效及安全性。方法102例2型糖尿病患者,随机分成两组:单用胰岛素治疗组(DM+INS组)50例,联合治疗组(DM+INS+RSG组)治疗组52例,在继续应用胰岛素治疗的基础上加服罗格列酮(Rosiglitazone,RSG)4mg/d,共三个月。观测两组治疗前后空腹血糖(FPG)及餐后血糖(PPG)、糖化血红蛋白(HgA1C)、甘油三酯(TG)、胆固醇(TC)、高密度脂蛋白(HDLC)、低密度脂蛋白(LDLC)和体重指数(BMI)的改变。结果DM+INS+RSG组与DM+INS组治疗前FPG、PPG、HbA1C、TC、TG、HDLC、LDLC和胰岛素用量无明显统计学差异(P>0.05)。DM+INS+RSG组治疗后1个月和3个月FPG、PPG、HbA1C均有明显的下降(P<0.05,P<0.01)。结论对单用胰岛素治疗血糖控制欠佳的2型糖尿病患者可加用胰岛素增敏剂罗格列酮治疗,可使血糖和糖化血红蛋白得以良好的控制。

A clinical trial of rosiglitazone combined with insulin in the treatment of type 2 diabetic patients

Objective To observe the efficacy and safety of rosiglitazone when added to insulin in the treatment of type 2 diabetic patients who are not good controlled in plasma glucose on insulin monotherapy.Methods 102 type 2 diabetic patients were randomized to insulin monotherapy group(DM+INS group)50 cases and rosiglitazone added to insulin group(DM+INS+RSG group)52 cases for 3 months treatment.The dosage of rosiglitazone was given 4 mg everyday in DM+INS+RSG group.The changes of laboratory datas including fasting plasma glucose(FPG),postprandial plasma glucose(PPG),hemoglobulin A_1C(HbA_1C),cholesteral(TC),triglyceride(TG),high density lipoprotein-cholesteral(HDL-C),low density lipoprotein cholesteral(LDL-C),body mass index(BMI)were measured before and after treatment in different groups.Results There were not significantly difference in FPG,PPG,HbA_1C,TC,TG,HDL-C,LDL-C and dosages of insulin in the baselin between DM+INS group and DM+INS+RSG group(P>0.05).There were significantly decrease in FPG,PPG and HbA_1C in the DM+INS+RSG group after 1 and 3 months treatment(P<0.05,P<0.01).Conclusion The addition of rosiglitazone to insulin treatment results in significantly improvement in glycemic control in the type 2 diabetic patients.